News



June - July 2014

Kauffman foundation scholars attend a two months internship program at Nika Biochemicals, Inc. Olathe, KS facilities.

  

June 2 -5th, 2013

Nika Biochemicals attends 75th Annual Conference for Veterinarians

http://www.k-state.edu/vet/annual-conf-13/

 

March 5th, 2013

Nika Biochemicals presents at One Health Summit, Kansas City

Session Two - 10:30am-11:45am Entrepreneur Boot Camp

Dr Hemant Joshi, Nika Biochemicals, Moderator

Dr Nick Franano, CEO, Novita

David Alburty, CEO, Alburty Labs

John Bucksath, CEO, ABC Laboratories

Mary Kay O'Connor, CEO, StartingPoint, LLC

Panel Discussion

 

December 7th, 2012

Nika Biochemicals attends ‘Pediatric Drug Development – Current Topics’ organized by American Association of Pharmaceuticals Scientists (AAPS) in Overland Park.

 

November 29-30, 2012

Nika Biochemicals attends International PRRS symposium at Kansas City, Missouri. The International PRRS Symposium is an annual public meeting hosted by the PRRS Coordinated Agricultural Project (CAP), National Swine Improvement Federation (NSIF),  Boehringer-Ingelheim Vetmedica, Inc., and the National Pork Board.

 

August 27th, 2012

Nika Biochemicals attends 2012 A. H. Research Symposium, Fast Forward: Accelerating Innovation to Commercialization at Kansas City held on August 27th, 2012

More details are available at this link: Fast Forward

 

August 1st, 2012:

Nika Biochemicals Inc. expands operations in the city of Olathe, KS. NBI will have laboratory and office space at The Kansas Biosciences Authority's Incubator. This presence solidifies NBI's commitment to clients of best practices in the biologics process development and scale up. NBI cares for the unmet needs of its clients to meet short supplies and increased demands for biopharmaceuticals.

 

July 17th, 2012

Nika Biochemicals' Dr. Joshi spoke at American Association of Pharmaceutical Sciences (AAPS-KCDG) Chapter.

Title "Designing and Implementing Viral Clearance Operations during Manufacturing of Antibodies"

Abstract:

Orthogonal virus clearance operations are considered during process development and scale up of an antibody product. Details of process centric, regulatory, filter centric and hardware considerations during design and implementation of a virus filtration operation will be discussed with examples. The log removal values, filtration area and process economics are balanced to achieve the end goal. This presentation is intended to bring the audience up-to-date on both the current understanding of industry and  regulatory agencies on viral clearance during manufacturing of antibodies.


May 14, 2012:

Nika announced today that it's is ready to offer contract manufacturing services for biologics. NBI's initial offering is 1L to 250L bioreactor and downstream processing capacity that will be expanded in near future. Manufacturing will be done at its facility in Kansas City.

NBI is ready to process a variety of biologics including bacterial, viral, recombinant and native proteins etc. NBI uses cutting edge disposable technology available for both upstream and downstream bioprocessing to provide clients with solutions and speed to market.

For further interests and information please contact our business development at bdm@nikabiochem.com

USDA News

GEN News

Comments